{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:36:38Z","timestamp":1787060198575,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14223-8","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:15:52Z","timestamp":1748344552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and quality of life of CDK4\/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Benlong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengkui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiding","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-xiaoxi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"14223_CR1","doi-asserted-by":"publisher","first-page":"1269922","DOI":"10.3389\/fphar.2024.1269922","volume":"15","author":"D Pu","year":"2024","unstructured":"Pu D, Wu Y, Xu D, Shi G, Chen H, Feng D, et al. The adverse events of CDK4\/6 inhibitors for HR+\/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials. Front Pharmacol. 2024;15:1269922.","journal-title":"Front Pharmacol"},{"key":"14223_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. Cancer J Clin. 2023;73:480\u2013515.","journal-title":"Cancer J Clin"},{"key":"14223_CR3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1186\/s12889-020-09375-0","volume":"20","author":"Y Ding","year":"2020","unstructured":"Ding Y, Chen X, Zhang Q, Liu Q. Historical trends in breast Cancer among women in China from age-period-cohort modeling of the 1990\u20132015 breast Cancer mortality data. BMC Public Health. 2020;20:1280.","journal-title":"BMC Public Health"},{"key":"14223_CR4","doi-asserted-by":"crossref","unstructured":"Clusan L, Ferriere F, Flouriot G, Pakdel F. A basic review on Estrogen receptor signaling pathways in breast Cancer. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms24076834"},{"key":"14223_CR5","doi-asserted-by":"crossref","unstructured":"Shete N, Calabrese J, Tonetti DA. Revisiting Estrogen for the treatment of Endocrine-Resistant breast cancer: novel therapeutic approaches. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15143647"},{"key":"14223_CR6","volume-title":"Breast cancer. Version 2.2024","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2024","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Version 2.2024. Fort Washington: National Comprehensive Cancer Network; 2024."},{"key":"14223_CR7","first-page":"1262","volume":"44","author":"Breast Cancer Expert Committee of National Cancer Quality Control C","year":"2022","unstructured":"Breast Cancer Expert Committee of National Cancer Quality Control C. Breast Cancer expert committee of China Anti-Cancer A, Cancer drug clinical research committee of China Anti-Cancer A. [Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2022 edition)]. Zhonghua Zhong Liu Za Zhi. 2022;44:1262\u201387.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"14223_CR8","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Stat 2022 CA: cancer J Clin. 2022;72:524\u201341.","journal-title":"Breast Cancer Stat 2022 CA: cancer J Clin"},{"key":"14223_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.hoc.2013.05.004","volume":"27","author":"G Schiavon","year":"2013","unstructured":"Schiavon G, Smith IE. Endocrine therapy for advanced\/metastatic breast cancer. Hematol Oncol Clin N Am. 2013;27:715\u201336. viii.","journal-title":"Hematol Oncol Clin N Am"},{"key":"14223_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12955-020-01591-x","volume":"18","author":"P Mokhtari-Hessari","year":"2020","unstructured":"Mokhtari-Hessari P, Montazeri A. Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes. 2020;18:338.","journal-title":"Health Qual Life Outcomes"},{"key":"14223_CR11","doi-asserted-by":"crossref","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024.","DOI":"10.1038\/s41417-024-00747-x"},{"key":"14223_CR12","doi-asserted-by":"publisher","first-page":"1340764","DOI":"10.3389\/fphar.2024.1340764","volume":"15","author":"LQ Cao","year":"2024","unstructured":"Cao LQ, Sun H, Xie Y, Patel H, Bo L, Lin H, et al. Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy. Front Pharmacol. 2024;15:1340764.","journal-title":"Front Pharmacol"},{"key":"14223_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646\u201357.","journal-title":"Lancet Oncol"},{"key":"14223_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast cancer. 2019;5:5.","journal-title":"NPJ Breast cancer"},{"key":"14223_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/fon-2018-0531","volume":"15","author":"C Darden","year":"2019","unstructured":"Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving Palbociclib combination therapies for advanced\/metastatic breast cancer. Future Oncol (London England). 2019;15:141\u201350.","journal-title":"Future Oncol (London England)"},{"key":"14223_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast Cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"14223_CR17","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study. Therapeutic Adv Med Oncol. 2020;12:1758835920963925.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"14223_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315.","journal-title":"Lancet Oncol"},{"key":"14223_CR19","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s00268-010-0683-1","volume":"34","author":"SP Leong","year":"2010","unstructured":"Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308\u201324.","journal-title":"World J Surg"},{"key":"14223_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1200\/GO.20.00316","volume":"6","author":"DW Lim","year":"2020","unstructured":"Lim DW, Giannakeas V, Narod SA. Survival differences in Chinese versus white women with breast Cancer in the united States: A SEER-Based analysis. JCO Glob Oncol. 2020;6:1582\u201392.","journal-title":"JCO Glob Oncol"},{"key":"14223_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","volume":"21","author":"S Verma","year":"2016","unstructured":"Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, et al. Palbociclib in combination with fulvestrant in women with hormone Receptor-Positive\/HER2-Negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, Placebo-Controlled, phase III study (PALOMA-3). Oncologist. 2016;21:1165\u201375.","journal-title":"Oncologist"},{"key":"14223_CR22","doi-asserted-by":"publisher","first-page":"175883592094306","DOI":"10.1177\/1758835920943065","volume":"12","author":"N Harbeck","year":"2020","unstructured":"Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Therapeutic Adv Med Oncol. 2020;12:1758835920943065.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"14223_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/cer.14.76","volume":"4","author":"J Nguyen","year":"2015","unstructured":"Nguyen J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res. 2015;4:157\u201366.","journal-title":"J Comp Eff Res"},{"key":"14223_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/pon.727","volume":"12","author":"WC Chie","year":"2003","unstructured":"Chie WC, Chang KJ, Huang CS, Kuo WH. Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology. 2003;12:729\u201335.","journal-title":"Psychooncology"},{"key":"14223_CR25","first-page":"592","volume":"13","author":"C Le Cai","year":"2004","unstructured":"Le Cai C, Wan X, Tang Y, Lu J, Luo Q, Meng, et al. Development and evaluation on measurement instrument of quality of life for patients with breast cancer: Chinese version of EORTC QLQ-BR23. Chin J Behav Med Sci. 2004;13:592\u20134.","journal-title":"Chin J Behav Med Sci"},{"key":"14223_CR26","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European organization for research and treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncology: Official J Am Soc Clin Oncol. 1996;14:2756\u201368.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14223_CR27","doi-asserted-by":"crossref","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2009<\u2009sup>\u2606. Annals of Oncology. 2021;32:1475-95.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"14223_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oncolo\/oyac075","volume":"27","author":"JM Martin","year":"2022","unstructured":"Martin JM, Handorf EA, Montero AJ, Goldstein LJ. Systemic therapies following progression on First-line CDK4\/6-inhibitor treatment: analysis of Real-world data. Oncologist. 2022;27:441\u20136.","journal-title":"Oncologist"},{"key":"14223_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10549-023-06993-1","volume":"201","author":"M Kruse","year":"2023","unstructured":"Kruse M, Smyth EN, Bowman L, Gautam S, Guimaraes CM, Nisbett AR, et al. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world. Breast Cancer Res Treat. 2023;201:105\u201315.","journal-title":"Breast Cancer Res Treat"},{"key":"14223_CR30","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on Cyclin-Dependent kinase 4\/6 Inhibition in hormone receptor-Positive, human epidermal growth factor receptor 2-Negative metastatic breast cancer: MAINTAIN trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41:4004\u201313.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14223_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/oncolo\/oyad207","volume":"28","author":"F Cardoso","year":"2023","unstructured":"Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, et al. Quality of life and Treatment-Related side effects in patients with HR+\/HER2- advanced breast cancer: findings from a multicountry survey. Oncologist. 2023;28:856\u201365.","journal-title":"Oncologist"},{"key":"14223_CR32","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.21037\/apm-21-1096","volume":"10","author":"L Yang","year":"2021","unstructured":"Yang L, Xue J, Yang Z, Wang M, Yang P, Dong Y, et al. Side effects of CDK4\/6 inhibitors in the treatment of HR+\/HER2\u2013\u2009advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Annals Palliat Med. 2021;10:5590\u20139.","journal-title":"Annals Palliat Med"},{"key":"14223_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone Receptor-Positive, ERBB2-Negative breast Cancer that progressed on endocrine Therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol. 2020;6:116\u201324.","journal-title":"JAMA Oncol"},{"key":"14223_CR34","doi-asserted-by":"crossref","unstructured":"Coelho A, Kendir C, Barrenho E, Klazinga N, Paiva C, Abreu de Sousa J et al. Patient-Reported outcomes and experiences assessment in women with breast cancer: Portuguese case study. Int J Environ Res Public Health. 2023;20.","DOI":"10.3390\/ijerph20042931"},{"key":"14223_CR35","doi-asserted-by":"publisher","first-page":"925534","DOI":"10.3389\/fonc.2022.925534","volume":"12","author":"K Zhou","year":"2022","unstructured":"Zhou K, Bellanger M, Le Lann S, Robert M, Frenel JS, Campone M. The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life. Front Oncol. 2022;12:925534.","journal-title":"Front Oncol"},{"key":"14223_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"14223_CR37","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.clinthera.2017.07.009","volume":"39","author":"R Wood","year":"2017","unstructured":"Wood R, Mitra D, de Courcy J, Iyer S. Patient-reported quality of life and treatment satisfaction in patients with HR(+)\/HER2(-) advanced\/metastatic breast Cancer. Clin Ther. 2017;39:1719\u201328.","journal-title":"Clin Ther"},{"key":"14223_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/cer-2021-0221","volume":"11","author":"E Law","year":"2022","unstructured":"Law E, Gavanji R, Walsh S, Haltner A, McTavish R, Cameron C. Palbociclib versus abemaciclib in HR+\/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J Comp Eff Res. 2022;11:109\u201320.","journal-title":"J Comp Eff Res"},{"key":"14223_CR39","doi-asserted-by":"publisher","first-page":"175883592311528","DOI":"10.1177\/17588359231152843","volume":"15","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Harmer V, O\u2019Shaughnessy J, Jhaveri K, Tolaney SM, Cardoso F, et al. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+\/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Therapeutic Adv Med Oncol. 2023;15:17588359231152843.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"14223_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","volume":"17","author":"S Lasheen","year":"2017","unstructured":"Lasheen S, Shohdy KS, Kassem L, Abdel-Rahman O. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2017;17:851\u20136.","journal-title":"Expert Rev Anticancer Ther"},{"key":"14223_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-017-4523-y","volume":"167","author":"GS Sonke","year":"2018","unstructured":"Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;167:659\u201369.","journal-title":"Breast Cancer Res Treat"},{"key":"14223_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, et al. Skin toxicities with Cyclin-Dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol. 2022;23:247\u201355.","journal-title":"Am J Clin Dermatol"},{"key":"14223_CR43","doi-asserted-by":"crossref","unstructured":"Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A et al. Cyclin-Dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV task force dermatology for Cancer patients international study. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15143658"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14223-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14223-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14223-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:16:00Z","timestamp":1748344560000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14223-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14223"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14223-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (Approval Number: 2209261-4) as the lead center, as well as by the ethics committee of all participating centers. The participants provided informed consent before completing the survey. The study was conducted following the tenets of the Declaration of Helsinki and the Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"951"}}